Other Pharmaceuticals - Netherlands

Netherlands

The Other Pharmaceuticals market in the Netherlands is expected to witness significant growth in the coming years.
By 2024, the projected revenue is estimated to reach €2.24bn.
This indicates a positive trend in the market, with an annual growth rate (CAGR 2024-2029) of 3.96%.
Consequently, the market volume is predicted to reach €2.72bn by 2029.
In terms of global comparison, United States is expected to generate the highest revenue in the Other Pharmaceuticals market, amounting to €241.60bn in 2024.
This emphasizes the dominance of the United States in the global pharmaceutical industry.
Netherlands is embracing innovative research and development in the field of other pharmaceuticals, fostering a thriving market for cutting-edge treatments and therapies.

Key regions: China, Europe, Australia, United States, Germany

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Other Pharmaceuticals market in Netherlands has been experiencing a steady growth in recent years.

Customer preferences: Customers in the Netherlands have a strong preference for generic drugs, which are cheaper than branded drugs. This has led to an increase in the demand for generic drugs in the country. Additionally, there has been a growing interest in natural and alternative medicines among Dutch consumers.

Trends in the market: The Other Pharmaceuticals market in the Netherlands has been growing steadily due to a number of factors. One of the key drivers of growth has been an aging population, which has led to an increase in the demand for drugs to treat age-related conditions. Another factor contributing to the growth of the market is the increasing prevalence of chronic diseases such as diabetes and cardiovascular diseases.

Local special circumstances: The Dutch healthcare system is highly regulated, with a focus on cost-effectiveness and efficiency. This has led to a number of cost-saving measures, such as the use of reference pricing and the promotion of generic drugs. Additionally, the government has implemented measures to promote the use of eHealth technologies, which has led to an increase in the use of digital health solutions in the country.

Underlying macroeconomic factors: The Dutch economy has been growing steadily in recent years, with a focus on innovation and technology. This has led to a number of opportunities for the pharmaceutical industry, particularly in the area of digital health. Additionally, the Netherlands is home to a number of leading pharmaceutical companies, which has helped to drive growth in the sector.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.